CMP 1401
Alternative Names: CMP-1401Latest Information Update: 20 Jan 2023
At a glance
- Originator CAMP Therapeutics
- Class Anti-infectives; Peptides
- Mechanism of Action Bacterial outer membrane protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Enterobacteriaceae infections; Pneumonia; Sepsis; Skin and soft tissue infections; Urinary tract infections
Most Recent Events
- 07 Dec 2022 Preclinical trials in Enterobacteriaceae infections in South Korea (IV) (CAMP Therapeutics pipeline, December 2022)
- 06 Dec 2022 Preclinical trials in Pneumonia in South Korea (IV) (CAMP Therapeutics pipeline, December 2022)
- 06 Dec 2022 Preclinical trials in Sepsis in South Korea (IV) (CAMP Therapeutics pipeline, December 2022)